Marimed (MRMD)
Marimed on one page: short interest, fails to deliver, financials, earnings dates and insider trades. Listed on OTC, classified by the SEC as medicinal chemicals & botanical products.
1K
Short interest
settlement 2026-09-30
1.0
Days to cover
unchanged vs prior
500
Fails to deliver
settlement 2026-09-30
Wed 4 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-10-15.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in MRMD is 1,000 shares, down 19,999 shares over the last month. Over the last 48 readings it ranged from 1,000 shares (30 September 2026) to 155,070 shares (28 February 2025). The latest reading sits at the bottom of that range. At the reported average volume of 1.7M shares a day that is 1.0 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/mrmd" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 1,000 | -97.8% | 1,661,239 | 1.00 |
| 2026-09-15 | 44,669 | +112.7% | 769,089 | 1.00 |
| 2026-08-31 | 20,999 | -4.3% | 1,828,278 | 1.00 |
| 2026-08-14 | 21,955 | +124.2% | 473,231 | 1.00 |
| 2026-07-31 | 9,792 | +151.5% | 433,915 | 1.00 |
| 2026-07-15 | 3,893 | +108.6% | 548,629 | 1.00 |
| 2026-06-30 | 1,866 | -88.4% | 668,174 | 1.00 |
| 2026-06-15 | 16,030 | -75.0% | 1,406,144 | 1.00 |
| 2026-05-29 | 64,138 | +1827.8% | 1,254,952 | 1.00 |
| 2026-05-15 | 3,327 | -84.0% | 1,290,557 | 1.00 |
| 2026-04-30 | 20,807 | -42.2% | 2,603,967 | 1.00 |
| 2026-04-15 | 36,003 | -45.2% | 1,232,829 | 1.00 |
| 2026-03-31 | 65,750 | +368.8% | 1,045,424 | 1.00 |
| 2026-03-13 | 14,026 | -43.6% | 679,274 | 1.00 |
| 2026-02-27 | 24,883 | +2327.6% | 976,778 | 1.00 |
| 2026-02-13 | 1,025 | +0.0% | 596,477 | 1.00 |
| 2026-01-30 | 1,025 | +0.0% | 742,894 | 1.00 |
| 2026-01-15 | 1,025 | -81.7% | 945,496 | 1.00 |
| 2025-12-31 | 5,595 | -85.0% | 4,605,275 | 1.00 |
| 2025-12-15 | 37,428 | +271.6% | 2,872,286 | 1.00 |
| 2025-11-28 | 10,071 | -81.7% | 1,799,107 | 1.00 |
| 2025-11-14 | 55,116 | +56.8% | 2,703,903 | 1.00 |
| 2025-10-31 | 35,143 | -62.2% | 2,941,441 | 1.00 |
| 2025-10-15 | 92,876 | -16.6% | 3,191,037 | 1.00 |
| 2025-09-30 | 111,348 | +352.1% | 2,032,135 | 1.00 |
| 2025-09-15 | 24,630 | +53.2% | 5,181,880 | 1.00 |
| 2025-08-29 | 16,078 | -66.2% | 4,684,875 | 1.00 |
| 2025-08-15 | 47,499 | +110.8% | 3,282,207 | 1.00 |
| 2025-07-31 | 22,531 | -48.9% | 596,583 | 1.00 |
| 2025-07-15 | 44,060 | +1633.3% | 1,091,511 | 1.00 |
| 2025-06-30 | 2,542 | -95.6% | 716,730 | 1.00 |
| 2025-06-13 | 57,766 | +28.6% | 672,905 | 1.00 |
| 2025-05-30 | 44,917 | -32.5% | 858,779 | 1.00 |
| 2025-05-15 | 66,532 | +29.7% | 1,002,035 | 1.00 |
| 2025-04-30 | 51,294 | -11.2% | 719,736 | 1.00 |
| 2025-04-15 | 57,777 | -10.5% | 1,047,107 | 1.00 |
| 2025-03-31 | 64,587 | +12.8% | 760,658 | 1.00 |
| 2025-03-14 | 57,262 | -63.1% | 723,407 | 1.00 |
| 2025-02-28 | 155,070 | +12.1% | 892,891 | 1.00 |
| 2025-02-14 | 138,283 | +70.7% | 1,090,832 | 1.00 |
| 2025-01-31 | 80,991 | +39.4% | 583,407 | 1.00 |
| 2025-01-15 | 58,097 | +868.3% | 513,402 | 1.00 |
| 2024-12-31 | 6,000 | -93.5% | 1,190,356 | 1.00 |
| 2024-12-13 | 91,809 | +3180.1% | 1,017,977 | 1.00 |
| 2024-11-29 | 2,799 | -96.0% | 1,222,584 | 1.00 |
| 2024-11-15 | 69,900 | +147.8% | 1,358,909 | 1.00 |
| 2024-10-31 | 28,205 | -77.5% | 737,458 | 1.00 |
| 2024-10-15 | 125,512 | +301.7% | 853,790 | 1.00 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 30 September 2026, the fails-to-deliver balance in MRMD is 500 shares, down 9,486 shares over the last settlement date. Over the last 30 readings it ranged from 27 shares (24 August 2026) to 95,112 shares (1 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-30 | 500 | $0.08 | $40 |
| 2026-09-23 | 9,986 | $0.07 | $699 |
| 2026-09-22 | 8,776 | $0.07 | $614 |
| 2026-09-18 | 2,557 | $0.07 | $179 |
| 2026-09-16 | 21,769 | $0.07 | $2K |
| 2026-09-15 | 21,369 | $0.08 | $2K |
| 2026-09-11 | 37,879 | $0.08 | $3K |
| 2026-09-10 | 470 | $0.08 | $38 |
| 2026-09-08 | 6,892 | $0.08 | $551 |
| 2026-08-28 | 46,591 | $0.09 | $4K |
| 2026-08-27 | 6,907 | $0.08 | $553 |
| 2026-08-24 | 27 | $0.09 | $2 |
| 2026-08-21 | 897 | $0.08 | $72 |
| 2026-08-18 | 884 | $0.07 | $62 |
| 2026-08-17 | 8,447 | $0.07 | $591 |
| 2026-08-14 | 8,327 | $0.07 | $583 |
| 2026-08-10 | 5,951 | $0.07 | $417 |
| 2026-08-07 | 5,951 | $0.07 | $417 |
| 2026-08-06 | 6,111 | $0.06 | $367 |
| 2026-08-03 | 7,847 | $0.06 | $471 |
| 2026-07-31 | 8,592 | $0.06 | $516 |
| 2026-07-30 | 17,592 | $0.07 | $1K |
| 2026-07-20 | 1,411 | $0.07 | $99 |
| 2026-07-17 | 4,011 | $0.07 | $281 |
| 2026-07-01 | 95,112 | $0.07 | $7K |
| 2026-06-30 | 90,989 | $0.07 | $6K |
| 2026-06-16 | 7,424 | $0.07 | $520 |
| 2026-06-02 | 20,951 | $0.08 | $2K |
| 2026-06-01 | 89,479 | $0.08 | $7K |
| 2026-05-29 | 31,053 | $0.08 | $2K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for MRMD in the last 90 days. The most recent filings are listed below. Latest filing: Crandall Ryan (Chief Commercial Officer) on 2026-10-15.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-15 | Crandall Ryan | Chief Commercial Officer | Tax withholding | 10K | $0.06 | $578 | 1.2M |
| 2026-10-15 | Crandall Ryan | Chief Commercial Officer | Exercise or conversion | 33K | $0.00 | $0 | 1.2M |
| 2026-10-15 | Levine Jon R | President and CEO | Tax withholding | 9K | $0.06 | $539 | 21.4M |
| 2026-10-15 | Levine Jon R | President and CEO | Exercise or conversion | 31K | $0.00 | $0 | 21.4M |
| 2026-10-15 | Pinho Mario | Chief Financial Officer | Tax withholding | 11K | $0.06 | $674 | 362K |
| 2026-10-15 | Pinho Mario | Chief Financial Officer | Exercise or conversion | 38K | $0.00 | $0 | 373K |
| 2026-10-15 | Shaw Timothy | Chief Operating Officer | Tax withholding | 13K | $0.06 | $751 | 9.5M |
| 2026-10-15 | Shaw Timothy | Chief Operating Officer | Exercise or conversion | 43K | $0.00 | $0 | 9.5M |
| 2026-10-02 | Shaw Timothy | Chief Operating Officer | Tax withholding | 3K | $0.07 | $241 | 9.5M |
| 2026-10-02 | Shaw Timothy | Chief Operating Officer | Exercise or conversion | 10K | $0.00 | $0 | 9.5M |
| 2026-10-02 | Levine Jon R | President and CEO | Tax withholding | 4K | $0.07 | $278 | 21.4M |
| 2026-10-02 | Levine Jon R | President and CEO | Exercise or conversion | 12K | $0.00 | $0 | 21.4M |
| 2026-09-28 | Crandall Ryan | Chief Commercial Officer | Tax withholding | 2K | $0.08 | $161 | 1.1M |
| 2026-09-28 | Crandall Ryan | Chief Commercial Officer | Exercise or conversion | 6K | $0.00 | $0 | 1.1M |
| 2026-09-01 | Shaw Timothy | Chief Operating Officer | Tax withholding | 23K | $0.08 | $2K | 9.5M |
| 2026-09-01 | Shaw Timothy | Chief Operating Officer | Exercise or conversion | 65K | $0.00 | $0 | 9.5M |
| 2026-07-15 | Shaw Timothy | Chief Operating Officer | Tax withholding | 15K | $0.07 | $979 | 9.4M |
| 2026-07-15 | Shaw Timothy | Chief Operating Officer | Exercise or conversion | 43K | $0.00 | $0 | 9.4M |
| 2026-07-15 | Pinho Mario | Chief Financial Officer | Tax withholding | 31K | $0.07 | $2K | 335K |
| 2026-07-15 | Pinho Mario | Chief Financial Officer | Exercise or conversion | 88K | $0.00 | $0 | 366K |
| 2026-07-15 | Selhub Eva M.D. | Director | Exercise or conversion | 173K | $0.00 | $0 | 731K |
| 2026-07-15 | Levine Jon R | President and CEO | Tax withholding | 11K | $0.07 | $703 | 21.4M |
| 2026-07-15 | Levine Jon R | President and CEO | Exercise or conversion | 31K | $0.00 | $0 | 21.4M |
| 2026-07-15 | Gildea Edward J | Director | Exercise or conversion | 192K | $0.00 | $0 | 1.2M |
| 2026-07-15 | Crandall Ryan | Chief Commercial Officer | Tax withholding | 11K | $0.07 | $753 | 1.1M |
| 2026-07-15 | Crandall Ryan | Chief Commercial Officer | Exercise or conversion | 33K | $0.00 | $0 | 1.1M |
| 2026-07-15 | Allen David R | Director | Exercise or conversion | 192K | $0.00 | $0 | 743K |
| 2026-06-15 | Crandall Ryan | Chief Commercial Officer | Exercise or conversion | 250K | $0.00 | $0 | 1.2M |
| 2026-06-15 | Crandall Ryan | Chief Commercial Officer | Tax withholding | 87K | $0.07 | $6K | 1.1M |
| 2026-06-12 | Gildea Edward J | Director | Exercise or conversion | 75K | $0.00 | $0 | 980K |
| 2026-06-12 | Selhub Eva M.D. | Director | Exercise or conversion | 75K | $0.00 | $0 | 558K |
| 2026-06-12 | Allen David R | Director | Exercise or conversion | 75K | $0.00 | $0 | 551K |
| 2026-06-08 | Crandall Ryan | Chief Commercial Officer | Tax withholding | 19K | $0.08 | $1K | 939K |
| 2026-06-08 | Crandall Ryan | Chief Commercial Officer | Exercise or conversion | 54K | $0.00 | $0 | 958K |
| 2026-05-29 | Shaw Timothy | Chief Operating Officer | Tax withholding | 14K | $0.08 | $1K | 9.4M |
| 2026-05-29 | Shaw Timothy | Chief Operating Officer | Exercise or conversion | 41K | $0.00 | $0 | 9.4M |
| 2026-05-29 | Levine Jon R | President and CEO | Tax withholding | 16K | $0.08 | $1K | 21.3M |
| 2026-05-29 | Levine Jon R | President and CEO | Exercise or conversion | 47K | $0.00 | $0 | 21.4M |
| 2026-05-29 | Crandall Ryan | Chief Commercial Officer | Tax withholding | 13K | $0.08 | $1K | 904K |
| 2026-05-29 | Crandall Ryan | Chief Commercial Officer | Exercise or conversion | 38K | $0.00 | $0 | 917K |
| 2026-05-22 | Levine Jon R | President and CEO | Buy | 20K | $0.07 | $1K | 21.3M |
| 2026-05-22 | Levine Jon R | President and CEO | Buy | 37K | $0.07 | $3K | 21.3M |
| 2026-05-22 | Levine Jon R | President and CEO | Buy | 3K | $0.08 | $230 | 21.3M |
| 2026-05-20 | Levine Jon R | President and CEO | Buy | 40K | $0.07 | $3K | 21.2M |
| 2026-05-07 | Levine Jon R | President and CEO | Tax withholding | 26K | $0.09 | $2K | 21.2M |
| 2026-05-07 | Levine Jon R | President and CEO | Exercise or conversion | 75K | $0.00 | $0 | 21.2M |
| 2026-04-02 | Shaw Timothy | Chief Operating Officer | Tax withholding | 3K | $0.07 | $239 | 9.4M |
| 2026-04-02 | Shaw Timothy | Chief Operating Officer | Exercise or conversion | 10K | $0.00 | $0 | 9.4M |
| 2026-04-02 | Levine Jon R | President and CEO | Tax withholding | 4K | $0.07 | $276 | 21.2M |
| 2026-04-02 | Levine Jon R | President and CEO | Exercise or conversion | 12K | $0.00 | $0 | 21.2M |
| 2026-03-28 | Crandall Ryan | Chief Commercial Officer | Tax withholding | 2K | $0.08 | $159 | 880K |
| 2026-03-28 | Crandall Ryan | Chief Commercial Officer | Exercise or conversion | 6K | $0.00 | $0 | 882K |
| 2026-03-07 | Shaw Timothy | Chief Operating Officer | Tax withholding | 8K | $0.08 | $631 | 9.4M |
| 2026-03-07 | Shaw Timothy | Chief Operating Officer | Exercise or conversion | 22K | $0.00 | $0 | 9.4M |
| 2026-03-07 | Levine Jon R | President and CEO | Tax withholding | 8K | $0.08 | $679 | 21.2M |
| 2026-03-07 | Levine Jon R | President and CEO | Exercise or conversion | 23K | $0.00 | $0 | 21.2M |
| 2026-03-07 | Crandall Ryan | Chief Commercial Officer | Tax withholding | 4K | $0.08 | $364 | 876K |
| 2026-03-07 | Crandall Ryan | Chief Commercial Officer | Exercise or conversion | 13K | $0.00 | $0 | 880K |
| 2026-03-01 | Shaw Timothy | Chief Operating Officer | Tax withholding | 23K | $0.08 | $2K | 9.3M |
| 2026-03-01 | Shaw Timothy | Chief Operating Officer | Exercise or conversion | 65K | $0.00 | $0 | 9.4M |
| 2026-01-15 | Pinho Mario | Chief Financial Officer | Tax withholding | 17K | $0.10 | $2K | 277K |
| 2026-01-15 | Pinho Mario | Chief Financial Officer | Exercise or conversion | 50K | $0.00 | $0 | 295K |
| 2025-12-31 | Pinho Mario | Chief Financial Officer | Tax withholding | 16K | $0.09 | $1K | 245K |
| 2025-12-31 | Pinho Mario | Chief Financial Officer | Exercise or conversion | 54K | $0.00 | $0 | 261K |
| 2025-12-15 | Selhub Eva M.D. | Director | Exercise or conversion | 167K | $0.00 | $0 | 483K |
| 2025-12-15 | Pinho Mario | Chief Financial Officer | Tax withholding | 5K | $0.11 | $505 | 207K |
| 2025-12-15 | Pinho Mario | Chief Financial Officer | Exercise or conversion | 16K | $0.00 | $0 | 212K |
| 2025-12-15 | Shaw Timothy | Chief Operating Officer | Tax withholding | 24K | $0.11 | $3K | 9.3M |
| 2025-12-15 | Shaw Timothy | Chief Operating Officer | Exercise or conversion | 82K | $0.00 | $0 | 9.3M |
| 2025-12-15 | Levine Jon R | President and CEO | Tax withholding | 26K | $0.11 | $3K | 21.1M |
| 2025-12-15 | Levine Jon R | President and CEO | Exercise or conversion | 90K | $0.00 | $0 | 21.2M |
| 2025-12-15 | Gildea Edward J | Director | Exercise or conversion | 247K | $0.00 | $0 | 905K |
| 2025-12-15 | Crandall Ryan | Chief Commercial Officer | Tax withholding | 18K | $0.11 | $2K | 868K |
| 2025-12-15 | Crandall Ryan | Chief Commercial Officer | Exercise or conversion | 63K | $0.00 | $0 | 886K |
| 2025-12-15 | Allen David R | Director | Exercise or conversion | 176K | $0.00 | $0 | 476K |
| 2025-12-12 | Shaw Timothy | Chief Operating Officer | Buy | 45K | $0.11 | $5K | 9.2M |
| 2025-12-08 | Crandall Ryan | Chief Commercial Officer | Tax withholding | 16K | $0.08 | $1K | 823K |
| 2025-12-08 | Crandall Ryan | Chief Commercial Officer | Exercise or conversion | 54K | $0.00 | $0 | 839K |
| 2025-11-29 | Shaw Timothy | Chief Operating Officer | Tax withholding | 24K | $0.09 | $2K | 9.2M |
| 2025-11-29 | Shaw Timothy | Chief Operating Officer | Exercise or conversion | 81K | $0.00 | $0 | 9.2M |
| 2025-11-29 | Levine Jon R | President and CEO | Tax withholding | 28K | $0.09 | $2K | 21.1M |
| 2025-11-29 | Levine Jon R | President and CEO | Exercise or conversion | 94K | $0.00 | $0 | 21.1M |
| 2025-11-29 | Crandall Ryan | Chief Commercial Officer | Tax withholding | 22K | $0.09 | $2K | 785K |
| 2025-11-29 | Crandall Ryan | Chief Commercial Officer | Exercise or conversion | 75K | $0.00 | $0 | 807K |
| 2025-11-07 | Levine Jon R | President and CEO | Tax withholding | 22K | $0.10 | $2K | 21.0M |
| 2025-11-07 | Levine Jon R | President and CEO | Exercise or conversion | 75K | $0.00 | $0 | 21.0M |
| 2025-10-27 | Shaw Timothy | Chief Operating Officer | Tax withholding | 33K | $0.16 | $5K | 9.1M |
| 2025-10-27 | Shaw Timothy | Chief Operating Officer | Exercise or conversion | 111K | $0.00 | $0 | 9.2M |
| 2025-10-27 | Levine Jon R | President and CEO | Tax withholding | 41K | $0.16 | $6K | 21.0M |
| 2025-10-27 | Levine Jon R | President and CEO | Exercise or conversion | 139K | $0.00 | $0 | 21.0M |
| 2025-10-02 | Shaw Timothy | Chief Operating Officer | Tax withholding | 3K | $0.16 | $472 | 9.1M |
| 2025-10-02 | Shaw Timothy | Chief Operating Officer | Exercise or conversion | 10K | $0.00 | $0 | 9.1M |
| 2025-10-02 | Levine Jon R | President and CEO | Tax withholding | 3K | $0.16 | $544 | 20.9M |
| 2025-10-02 | Levine Jon R | President and CEO | Exercise or conversion | 12K | $0.00 | $0 | 20.9M |
| 2025-09-30 | Pinho Mario | Chief Financial Officer | Tax withholding | 15K | $0.16 | $3K | 196K |
| 2025-09-30 | Pinho Mario | Chief Financial Officer | Exercise or conversion | 54K | $0.00 | $0 | 211K |
| 2025-09-28 | Crandall Ryan | Chief Commercial Officer | Tax withholding | 2K | $0.14 | $254 | 732K |
| 2025-09-28 | Crandall Ryan | Chief Commercial Officer | Exercise or conversion | 6K | $0.00 | $0 | 734K |
| 2025-09-15 | Shaw Timothy | Chief Operating Officer | Tax withholding | 24K | $0.14 | $3K | 9.0M |
| 2025-09-15 | Shaw Timothy | Chief Operating Officer | Exercise or conversion | 82K | $0.00 | $0 | 9.1M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Marimed reported revenue of $41.9M, up 6.1% from the same quarter a year earlier, and net loss of $3.6M (-0.01 diluted EPS). In FY 2025 it generated $7.7M of operating cash flow.
- Debt
- $82.7M
- Total assets
- $197.2M
- Shares outstanding
- 403,040,674
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $41.9M | -$3.6M | -8.6% | -0.01 |
| Q1 FY 2026 | 2026-03-31 | $39.5M | -$3.8M | -9.6% | -0.01 |
| Q4 FY 2025derived | 2025-12-31 | $41.6M | -$4.6M | -11.1% | n/a |
| Q3 FY 2025 | 2025-09-30 | $40.8M | -$2.9M | -7.2% | -0.01 |
| Q2 FY 2025 | 2025-06-30 | $39.5M | -$1.4M | -3.5% | 0.00 |
| Q1 FY 2025 | 2025-03-31 | $37.9M | -$5.5M | -14.5% | -0.01 |
| Q4 FY 2024derived | 2024-12-31 | $38.7M | -$8.5M | -22.0% | n/a |
| Q3 FY 2024 | 2024-09-30 | $40.6M | -$1.0M | -2.5% | 0.00 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $159.8M | -$14.5M | $7.7M | $1.2M | n/a | n/a |
| FY 2024 | 2024-12-31 | $157.7M | -$12.5M | $6.8M | $12.0M | n/a | n/a |
| FY 2023 | 2023-12-31 | $148.6M | -$16.0M | $7.9M | $20.1M | n/a | n/a |
| FY 2022 | 2022-12-31 | $134.0M | $13.5M | $7.3M | $12.1M | n/a | n/a |
| FY 2021 | 2021-12-31 | $121.5M | $7.2M | $35.9M | $17.9M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-10 from the cover page.
What this page is
Marimed in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Marimed (MRMD), SEC CIK 1522767, listed on OTC, classified by the SEC as medicinal chemicals & botanical products. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-05-13.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-15.JSON and CSV
- Company record
- EDGAR filing index for CIK 1522767Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as medicinal chemicals & botanical products
Other company pages
- MLMMartin Marietta Materials
- MMM3M
- MNSTMonster Beverage
- MOAltria Group
- MODModine Manufacturing
- MOSMosaic
- MPMP Materials
- MPCMarathon Petroleum
- MPWRMonolithic Power Systems
- MRKMerck
- MRNAModerna
- MRSHMarsh & McLennan Companies
- MRVLMarvell Technology
- MSMorgan Stanley
- MSCIMSCI
- MSFTMicrosoft
- MSIMotorola Solutions
- MSTRStrategy
Datasets
Frequently Asked Questions
How much of MRMD is sold short?
1,000 shares were held short at the 2026-09-30 settlement, 1.0 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is MRMD's daily short volume?
No daily short volume file lists MRMD yet.
Does MRMD have fails to deliver?
The SEC's latest file shows 500 MRMD shares failed to deliver at settlement 2026-09-30. Fails are reported per settlement date and published twice a month with a lag.
Are MRMD insiders buying or selling?
No open-market insider trades were reported for MRMD in the last 90 days. The most recent filings are listed below. Latest filing: Crandall Ryan (Chief Commercial Officer) on 2026-10-15.
What did MRMD report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Marimed reported revenue of $41.9M, up 6.1% from the same quarter a year earlier, and net loss of $3.6M (-0.01 diluted EPS). In FY 2025 it generated $7.7M of operating cash flow.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.